Association of cystatin C with left ventricular structure and function

The Dallas Heart Study

Parag C. Patel, Colby R. Ayers, Sabina A. Murphy, Ronald Peshock, Amit Khera, James A. De Lemos, Jody A. Balko, Sachin Gupta, Pradeep P A Mammen, Mark H. Drazner, David W. Markham

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalCirculation: Heart Failure
Volume2
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Cystatin C
Left Ventricular Function
Stroke Volume
Glomerular Filtration Rate
Kidney
Diet Therapy
Confounding Factors (Epidemiology)
Congenital Heart Defects
Left Ventricular Hypertrophy
Creatinine
Heart Failure
Phenotype

Keywords

  • Concentricity
  • Cystatin C
  • Dallas Heart Study
  • Hypertension
  • Left ventricular hypertrophy
  • Rrenal function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Patel, P. C., Ayers, C. R., Murphy, S. A., Peshock, R., Khera, A., De Lemos, J. A., ... Markham, D. W. (2009). Association of cystatin C with left ventricular structure and function: The Dallas Heart Study. Circulation: Heart Failure, 2(2), 98-104. https://doi.org/10.1161/CIRCHEARTFAILURE.108.807271

Association of cystatin C with left ventricular structure and function : The Dallas Heart Study. / Patel, Parag C.; Ayers, Colby R.; Murphy, Sabina A.; Peshock, Ronald; Khera, Amit; De Lemos, James A.; Balko, Jody A.; Gupta, Sachin; Mammen, Pradeep P A; Drazner, Mark H.; Markham, David W.

In: Circulation: Heart Failure, Vol. 2, No. 2, 03.2009, p. 98-104.

Research output: Contribution to journalArticle

Patel, PC, Ayers, CR, Murphy, SA, Peshock, R, Khera, A, De Lemos, JA, Balko, JA, Gupta, S, Mammen, PPA, Drazner, MH & Markham, DW 2009, 'Association of cystatin C with left ventricular structure and function: The Dallas Heart Study', Circulation: Heart Failure, vol. 2, no. 2, pp. 98-104. https://doi.org/10.1161/CIRCHEARTFAILURE.108.807271
Patel, Parag C. ; Ayers, Colby R. ; Murphy, Sabina A. ; Peshock, Ronald ; Khera, Amit ; De Lemos, James A. ; Balko, Jody A. ; Gupta, Sachin ; Mammen, Pradeep P A ; Drazner, Mark H. ; Markham, David W. / Association of cystatin C with left ventricular structure and function : The Dallas Heart Study. In: Circulation: Heart Failure. 2009 ; Vol. 2, No. 2. pp. 98-104.
@article{a1a117110d5f4baab723f01f8b7af3c4,
title = "Association of cystatin C with left ventricular structure and function: The Dallas Heart Study",
abstract = "Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.",
keywords = "Concentricity, Cystatin C, Dallas Heart Study, Hypertension, Left ventricular hypertrophy, Rrenal function",
author = "Patel, {Parag C.} and Ayers, {Colby R.} and Murphy, {Sabina A.} and Ronald Peshock and Amit Khera and {De Lemos}, {James A.} and Balko, {Jody A.} and Sachin Gupta and Mammen, {Pradeep P A} and Drazner, {Mark H.} and Markham, {David W.}",
year = "2009",
month = "3",
doi = "10.1161/CIRCHEARTFAILURE.108.807271",
language = "English (US)",
volume = "2",
pages = "98--104",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Association of cystatin C with left ventricular structure and function

T2 - The Dallas Heart Study

AU - Patel, Parag C.

AU - Ayers, Colby R.

AU - Murphy, Sabina A.

AU - Peshock, Ronald

AU - Khera, Amit

AU - De Lemos, James A.

AU - Balko, Jody A.

AU - Gupta, Sachin

AU - Mammen, Pradeep P A

AU - Drazner, Mark H.

AU - Markham, David W.

PY - 2009/3

Y1 - 2009/3

N2 - Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.

AB - Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.

KW - Concentricity

KW - Cystatin C

KW - Dallas Heart Study

KW - Hypertension

KW - Left ventricular hypertrophy

KW - Rrenal function

UR - http://www.scopus.com/inward/record.url?scp=67650624206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650624206&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.108.807271

DO - 10.1161/CIRCHEARTFAILURE.108.807271

M3 - Article

VL - 2

SP - 98

EP - 104

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 2

ER -